P1.27. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Baohui Han
Meta Tag
Speaker Baohui Han
Topic Early-Stage NSCLC: Innovation & New Technology
clinical trial
Efficacy and Safety
adjuvant therapy
Resectable Stage I NSCLC
high-grade patterns
EGFR Mutations
WCLC 2023
third-generation EGFR-TKI
Powered By